Pharmaron Beijing Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Pharmaron Beijing ha un patrimonio netto totale di CN¥14.0B e un debito totale di CN¥5.4B, che porta il suo rapporto debito/patrimonio netto a 38.7%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥23.6B e CN¥9.5B. L'EBIT di Pharmaron Beijing è CN¥1.5B rendendo il suo rapporto di copertura degli interessi -3.3. Ha liquidità e investimenti a breve termine pari a CN¥2.6B.

Informazioni chiave

38.7%

Rapporto debito/patrimonio netto

CN¥5.43b

Debito

Indice di copertura degli interessi	-3.3x
Contanti	CN¥2.60b
Patrimonio netto	CN¥14.03b
Totale passività	CN¥9.54b
Totale attività	CN¥23.57b

Aggiornamenti recenti sulla salute finanziaria

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Feb 27

Recent updates

At CN¥29.44, Is It Time To Put Pharmaron Beijing Co., Ltd. (SZSE:300759) On Your Watch List?

Nov 15

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth

Sep 27

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate

Sep 20

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price

May 12

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Mar 04

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Feb 27

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥7.1B ) di 300759 superano le sue passività a breve termine ( CN¥4.2B ).

Passività a lungo termine: Le attività a breve termine di 300759 ( CN¥7.1B ) superano le sue passività a lungo termine ( CN¥5.4B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 20.2% ) di 300759 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 300759 si è ridotto da 48.6% a 38.7% negli ultimi 5 anni.

Copertura del debito: Il debito di 300759 è ben coperto dal flusso di cassa operativo ( 46% ).

Copertura degli interessi: 300759 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Pharmaron Beijing Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Recent updates

At CN¥29.44, Is It Time To Put Pharmaron Beijing Co., Ltd. (SZSE:300759) On Your Watch List?

Price target increased by 10.0% to CN¥28.22

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 9.1% to CN¥25.66

Investor sentiment deteriorates as stock falls 25%

New minor risk - Share price stability

Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth

Investor sentiment improves as stock rises 17%

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate

Second quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.25 in 2Q 2023)

Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Price target decreased by 12% to CN¥22.71

Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024

Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price

Pharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.

First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.20 in 1Q 2023)

Pharmaron Beijing Co., Ltd. Announces Executive Changes

Consensus EPS estimates fall by 14%

Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Price target decreased by 7.3% to CN¥29.29

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorates as stock falls 16%

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023

Now 24% undervalued after recent price drop

Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

President recently sold CN¥231m worth of stock

Executive VP & Executive Director recently sold CN¥22m worth of stock

Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 2Q 2022)

Price target decreased by 8.9% to CN¥35.78

Price target decreased by 9.2% to CN¥36.68

Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 27, 2023

Price target decreased by 10% to CN¥58.29

President recently sold CN¥13m worth of stock

Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2022

Investor sentiment deteriorates as stock falls 16%

Now 21% undervalued after recent price drop

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.21 in 1Q 2022)

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 10% to CN¥69.70

Consensus EPS estimates fall by 19%

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 10% to CN¥75.56

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2022

Executive VP & Executive Director recently sold CN¥21m worth of stock

President recently sold CN¥31m worth of stock

President recently sold CN¥72m worth of stock

President recently sold CN¥24m worth of stock

President recently sold CN¥41m worth of stock

President recently sold CN¥48m worth of stock

President recently sold CN¥131m worth of stock

Price target decreased to CN¥81.79

Less than half of directors are independent

Price target decreased to CN¥87.07

Price target decreased to CN¥91.49

Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into equity transfer agreement to acquire 21.6874% stake in Pharmaron (Chengdu) Clinical Services Co., Ltd from Mr. Yu Wu and Mr. Li Xianghao for RMB 506.79 million.

Third quarter 2022 earnings released

Price target decreased to CN¥94.38

Investor sentiment improved over the past week

Pharmaron Beijing Co., Ltd. to Report Nine Months, 2022 Results on Oct 27, 2022

Pharmaron Beijing Co., Ltd. Announces Board Appointments

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Price target decreased to CN¥103